1. Home
  2. MGEE vs WGS Comparison

MGEE vs WGS Comparison

Compare MGEE & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MGE Energy Inc

MGEE

MGE Energy Inc

N/A

Current Price

$77.23

Market Cap

3.0B

Sector

Energy

ML Signal

N/A

Logo GeneDx Holdings Corp.

WGS

GeneDx Holdings Corp.

N/A

Current Price

$91.78

Market Cap

2.6B

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
MGEE
WGS
Founded
1855
2017
Country
United States
United States
Employees
N/A
1300
Industry
Electric Utilities: Central
Retail: Computer Software & Peripheral Equipment
Sector
Energy
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
2.6B
IPO Year
2001
N/A

Fundamental Metrics

Financial Performance
Metric
MGEE
WGS
Price
$77.23
$91.78
Analyst Decision
Sell
Strong Buy
Analyst Count
2
7
Target Price
$78.00
$140.71
AVG Volume (30 Days)
90.1K
738.9K
Earning Date
05-25-2026
01-01-0001
Dividend Yield
2.38%
N/A
EPS Growth
11.71
N/A
EPS
3.72
N/A
Revenue
N/A
N/A
Revenue This Year
$4.02
$29.98
Revenue Next Year
$2.77
$24.85
P/E Ratio
$21.44
$1,251.58
Revenue Growth
N/A
N/A
52 Week Low
$76.47
$55.17
52 Week High
$94.78
$170.87

Technical Indicators

Market Signals
Indicator
MGEE
WGS
Relative Strength Index (RSI) 35.79 51.26
Support Level N/A $78.80
Resistance Level $82.75 $95.94
Average True Range (ATR) 1.68 5.68
MACD -0.50 2.40
Stochastic Oscillator 10.14 83.97

Price Performance

Historical Comparison
MGEE
WGS

About MGEE MGE Energy Inc

MGE Energy provides electric service to 170,000 customers and natural gas service to 180,000 customers in Madison, Wisconsin, and surrounding areas. Nearly 90% of customers are residential. The company also owns a 3.6% stake in American Transmission Co. MGE owns interests in two coal power plants that earn guaranteed fixed rates of return, contributing about 20% of earnings.

About WGS GeneDx Holdings Corp.

GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.

Share on Social Networks: